ADARx Pharmaceuticals, Inc. (ADRX) vs Mesoblast Limited (MESO)

ADARx Pharmaceuticals, Inc. ADRX 14.37 −3.62%
Mesoblast Limited MESO 13.21 +0.84%

ADARx Pharmaceuticals, Inc. and Mesoblast Limited are both Biotechnology companies. ADARx Pharmaceuticals, Inc. and Mesoblast Limited are of similar size ($1.7B and $1.7B).

Metric	ADRX	MESO	Biotechnology median
P/E	—	n/m	11.36
P/S	—	136.96	9.12
P/B	—	1.79	2.14
Price to free cash flow	—	n/m	26.34
EV/EBITDA	—	n/m	0.62
EV/Sales	—	136.55	8.56
Earnings yield	—	(8.48%)	(34.18%)
Free cash flow yield	—	(8.21%)	(23.62%)

Metric	ADRX	MESO	Biotechnology median
Gross margin	—	(269.72%)	67.24%
Operating margin	—	(826.28%)	0.00%
Net margin	—	(1,091.71%)	0.00%
Free cash flow margin	—	0.00%	0.00%
Return on equity	—	0.00%	(50.28%)
Return on assets	—	0.00%	(45.89%)
Return on invested capital	—	0.00%	0.00%

Metric	ADRX	MESO	Biotechnology median
Revenue growth (TTM)	—	(26.54%)	6.96%
EPS growth (last fiscal year)	—	48.24%	29.86%
Revenue growth, 5-year CAGR	—	74.39%	9.75%
Net income growth, 5-year CAGR	—	0.00%	0.00%

Metric	ADRX	MESO	Biotechnology median
Debt to equity	—	0.22	0.00
Current ratio	—	1.58	4.72
Net debt to EBITDA	—	(0.67)	1.01

Metric	ADRX	MESO	Biotechnology median
Dividend yield	—	—	0.39%
Payout ratio	—	—	—

Metric	ADRX	MESO	Biotechnology median
Market cap	1.65b	1.70b	167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack